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Introduction {#sec005}
============

Diabetic foot infections are a well-recognised risk factor for hospitalisation and amputation \[[@pone.0177916.ref001]--[@pone.0177916.ref005]\]. According to a recent meta-analysis one in every 30 hospitalised patients at any given time is affected by a diabetic foot infection \[[@pone.0177916.ref006]\]. Additionally, patients with diabetes who develop an infection have been reported to have a 155-fold increased risk of amputation compared to those who do not \[[@pone.0177916.ref005]\]. Nearly all diabetic foot infections originate in a diabetic foot ulcer (DFU) \[[@pone.0177916.ref003]--[@pone.0177916.ref006]\] and the prevalence of these infections in DFUs have been reported to range between 25--60% \[[@pone.0177916.ref003]--[@pone.0177916.ref005], [@pone.0177916.ref007]--[@pone.0177916.ref010]\]. Although the critical nature and prevalence of infected DFUs are well appreciated \[[@pone.0177916.ref001]--[@pone.0177916.ref010]\], the development of these infections in the first place has received less attention \[[@pone.0177916.ref005], [@pone.0177916.ref011]\].

One prospective study of 1,666 diabetes patients reported a 9% incidence for developing a foot infection over a two-year follow up period \[[@pone.0177916.ref005]\]. Furthermore, the same study indicated a 61% incidence for developing a foot infection over a similar two-year period in a subgroup of 247 patients with a DFU; however, this subgroup included patients presenting with a mix of uninfected and infected DFUs \[[@pone.0177916.ref005]\]. Similarly, a small number of studies have investigated the risk factors for developing a diabetic foot infection and report patients presenting with peripheral neuropathy, peripheral arterial disease, previous DFUs and deep DFUs are more likely to develop diabetic foot infections \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]. However, to our knowledge no study has specifically investigated the incidence and risk factors for developing an infection in a population of patients presenting with an uninfected DFU. Thus, the primary aim of this study was to investigate the incidence and risk factors for developing an infection in patients presenting with an uninfected DFU. A secondary aim was to investigate the incidence of infection in patients with different DFU types and different DFU healing time durations.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

This study was a secondary analysis of data collected from a validated prospective state-wide clinical diabetic foot database in Queensland, Australia (Queensland High Risk Foot Form Database \[[@pone.0177916.ref012], [@pone.0177916.ref013]\]). The study received multi-site ethical approvals from two Australian Human Research Ethics Committees (HRECs); The Prince Charles Hospital (HREC/15/QPCH/177) and the Queensland University of Technology (1500000700). Furthermore, the study received legal approvals from the Queensland Statewide Diabetes Clinical Network Data Access committee and a Queensland Public Health Act 2005 waiver (QCHO/009321/RD006012) to use confidential de-identified information from the database for the purposes of this study. Thus, individual consent was not required or available for this study.

Settings and participants {#sec008}
-------------------------

Queensland is the third largest Australian state in terms of population, second largest in area and the most decentralised state with extremely diverse demography and geography \[[@pone.0177916.ref014]\]. Patients attending an outpatient Diabetic Foot Service in 13 of the 17 Hospital and Health Service areas in Queensland for treatment have their diabetic foot clinical data captured at each visit on a validated Queensland High Risk Foot Form (QHRFF) \[[@pone.0177916.ref012], [@pone.0177916.ref013], [@pone.0177916.ref015]\]. The QHRFF data is then collated and cleaned in the centralised QHRFF database for DFU healing and recurrence clinical benchmarking and research purposes \[[@pone.0177916.ref012], [@pone.0177916.ref013]\].

Eligible patients for this study were patients attending an aforementioned Diabetic Foot Service in Queensland for their first clinical visit that recorded an uninfected DFU between 1^st^ January 2012 and 31^st^ December 2013. The first clinical visit was defined as the first date the patient attended the Diabetic Foot Service between 1^st^ January 2012 and 31^st^ December 2013. A patient may have attended the service prior to 2012; however, this data was not captured for this study. A DFU was defined as a full thickness wound beneath the ankle on a patient with diabetes \[[@pone.0177916.ref004], [@pone.0177916.ref012]\]. An uninfected DFU was defined according to the International Working Group on the Diabetic Foot classification system as having no clinical signs or symptoms of infection \[[@pone.0177916.ref016], [@pone.0177916.ref017]\]. Patients were then followed from their first clinical visit until their DFU healed or if it did not heal for 12 months. Exclusion criteria included patients who did not have their infection status recorded at their first clinical visit (baseline) or at follow up visits prior to their DFU healing or if it did not heal prior to 12 months (follow up).

Variables collected {#sec009}
-------------------

For the purposes of this study the explanatory variables were those collected using the QHRFF at the patient's first clinical visit. If data were missing for a variable, the second visit's data was used for that variable(s) if available, provided the second visit was within one month of the first visit. The QHRFF data collection procedures, methods and definitions have been reported in detail elsewhere \[[@pone.0177916.ref012], [@pone.0177916.ref013], [@pone.0177916.ref018]\]. In brief, the QHRFF has been reported to be valid and reliable for the capture of multiple self-reported and clinically diagnosed variables when collected by clinicians with a range of diabetic foot disease experience \[[@pone.0177916.ref012]\].

The self-reported variables included: demographic (age, sex, indigenous status and residential postcode); diabetes history (diabetes type, diabetes duration, glycated haemoglobin (HbA1c) and blood glucose levels (BGLs) \>15 mmol/L in the previous 14 days); medical history (hypertension, dyslipidaemia, cardiovascular disease, chronic kidney disease and smoking status); foot disease history (previous foot ulcer and previous amputation); and past foot treatment in the previous 14 days (by podiatrist, general practitioner, surgeon, physician, nurse, orthotists or other) \[[@pone.0177916.ref012]\]. Patient's postcode of residence was transformed into the social determinant variables of socioeconomic status (according to the Australian Index of Relative Social Disadvantage \[[@pone.0177916.ref019]\]) and geographical remoteness status (according to the Accessibility/Remoteness Index of Australia \[[@pone.0177916.ref020]\]).

The clinically diagnosed variables included: foot risk factors (peripheral neuropathy (PN), lack of protective sensation to a 10-gram monofilament on at least 2 of 3 plantar forefoot locations \[[@pone.0177916.ref021], [@pone.0177916.ref022]\]; peripheral arterial disease (PAD), toe systolic pressure \<70 mmHg \[[@pone.0177916.ref021], [@pone.0177916.ref022]\]; foot deformity, scored at least 3 points on a 6-point foot deformity score \[[@pone.0177916.ref022]\]; suspected acute Charcot foot, red, hot, swollen, unilateral neuropathic foot joint without a DFU near the suspected Charcot joint \[[@pone.0177916.ref022]\]); foot ulcer characteristics (ulcer surface area (mm^2^); grade and depth, according to the University of Texas Diabetic Wound Classification System \[[@pone.0177916.ref004]\]; deep ulcers, scored a 2 ("wound penetrating to tendon or capsule") or 3 ("wound penetrating to bone or joint") \[[@pone.0177916.ref004]\]; and infection status according to the International Working Group on the Diabetic Foot classification system \[[@pone.0177916.ref016], [@pone.0177916.ref017]\]) \[[@pone.0177916.ref012]\]. DFU treatment provided on the first clinical visit was also recorded, including if the DFU was treated with: sharp debridement; appropriate wound dressings; prescribed antibiotics; optimum offloading in a cast walker; appropriate footwear; and patient education on DFU care \[[@pone.0177916.ref012], [@pone.0177916.ref022]\]. Lastly, foot ulcer healing time was captured and defined by subtracting the date of first clinical visit (as defined above) from the date the ulcer was recorded as healed (complete epithelialisation) \[[@pone.0177916.ref004], [@pone.0177916.ref012]\]. Ulcer healing time was categorised into: i) healed \<3 months (\<90 days since first visit), ii) healed between 3--12 months (91--365 days), iii) not healed at 12 months (ulcer had not healed at 365 days since first clinical visit).

The primary outcome variable for this study was the development of a foot infection prior to when the DFU healed or if the DFU did not heal then prior to 12-months after the first clinical visit. Foot infection was defined according to the International Working Group on the Diabetic Foot classification system as at least two clinical signs or symptoms of infection in or around the DFU including purulence, erythema, pain, tenderness, warmth and/or induration \[[@pone.0177916.ref016], [@pone.0177916.ref017], [@pone.0177916.ref023]\]. Patients were also sub-grouped into the following types of DFU: neuropathic (PN and no PAD), ischaemic (PAD and no PN), neuro-ischaemic (PN and PAD), post-surgical (recent non-healed minor amputation procedure regardless of PN or PAD), other (none of the aforementioned DFU types) or unknown (PN, PAD or post-surgical was not recorded). For patients with multiple DFUs a combined surface area of the multiple DFU was calculated, and the DFU type, grade, depth and treatment characteristics for the worst DFU used \[[@pone.0177916.ref012]\].

Statistical analyses {#sec010}
--------------------

Statistical analyses were performed with IBM SPSS 23.0 Statistics for Windows (SPSS Inc., Chicago, IL, USA) or GraphPad Software. Categorical variables were expressed as proportions (%) and continuous variables were expressed as a mean (standard deviation (SD)). Incidence was expressed as the proportion (%) of patients developing an infection of eligible patients; for overall patients, different DFU types, and ulcer healing time categories. For categorical variables Pearson's chi-squared tests were used to test for any differences between groups (*p*\<0.05) and Fisher's exact test with Bonferroni corrections were used for post-hoc pairwise comparisons (*p*\<0.005) \[[@pone.0177916.ref024], [@pone.0177916.ref025]\]. For continuous variables analysis of variance (ANOVA) with Tukey's post-hoc test used were used to test for differences between groups (*p*\<0.05) \[[@pone.0177916.ref024], [@pone.0177916.ref025]\]. Univariate logistic regression analyses were used to test for crude associations (*p*\<0.1) \[[@pone.0177916.ref026]\]. All variables achieving a crude association were included in a multivariate logistic regression analysis to test for independent risk factors \[[@pone.0177916.ref026]\]. A backwards stepwise method was used to remove non-significant variables (*p*\>0.05) at each step until only variables reaching statistical significance remained (*p*\<0.05) \[[@pone.0177916.ref026], [@pone.0177916.ref027]\]. If collinearity was identified using a correlation matrix (\>0.9) the variables with the lowest odds ratio was excluded \[[@pone.0177916.ref026]\]. Hosmer and Lemeshow goodness of fit, Omnibus degrees of freedom, Negelkerke pseudo R^2^ tests and significance were assessed at each step \[[@pone.0177916.ref026], [@pone.0177916.ref027]\]. Missing data were treated by excluding cases with missing data as the proportion of missing data were \<5% in the model \[[@pone.0177916.ref026]\].

Results {#sec011}
=======

Overall, 922 patients were eligible for inclusion in this study. Of these 69 (7.5%) patients were excluded: 53 (5.7%) because their infection status was not recorded at baseline and 16 (1.7%) because their infection status was not recorded on follow up. The remaining 853 included patients had a mean age (SD) of 62.9 (12.8) years, 68.0% were male, 13.6% were indigenous and 90.9% had type 2 diabetes. After the 12 month follow up period 454 (53.2%) patients' DFUs healed \<3 months, 222 (26.0%) healed between 3--12 months and 177 (20.8%) had not healed at 12 months.

[Table 1](#pone.0177916.t001){ref-type="table"} displays the patient characteristics for the different DFU types: 316 (37.0%) had neuropathic, 242 (28.4%) neuro-ischemic, 53 (6.2%) ischemic, 68 (8.0%) post-surgical, 41 (4.8%) other and 133 (15.6%) unknown DFU types. Differences between patients with different DFU types included: ischaemic ulcer patients were of older age (*p*\<0.05), more had hypertension and cardiovascular disease, and fewer had previous foot ulcers (all *p*\<0.005); neuro-ischaemic ulcer patients were also of older age (*p*\<0.05), more had chronic kidney disease, previous amputations and past foot treatment from an orthotist (all *p*\<0.005); post-surgical ulcer patients had larger ulcer surface areas (*p*\<0.05) and more had previous amputations (*p*\<0.005); other ulcer patients had fewer males, foot deformities, optimum offloading treatment and appropriate footwear treatment (all *p*\<0.005); and, patients with unknown ulcer types had fewer BGLs \>15 mmol/L, hypertension, dyslipidaemia, CVD and smokers, and more had previous foot ulcers (all *p*\<0.005). Although no differences existed for diabetes duration and HbA1c, it is noted that data on these two variables were missing in \>50% of patients.

10.1371/journal.pone.0177916.t001

###### Participant characteristics for each diabetic foot ulcer type (number (%) unless otherwise stated).

![](pone.0177916.t001){#pone.0177916.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 n     All\           Neuropathic                                Ischaemic                                           Neuro-Ischaemic                                     Post-Surgical                                         Other                                               Unknown                                              *p* Value
  -------------------------------------------------------------- ----- -------------- ------------------------------------------ --------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- ----------------------------------------------
  **Patients**                                                   853   853            316                                        53                                                  242                                                 68                                                    41                                                  133                                                  

  **Demographics**                                                                                                                                                                                                                                                                                                                                                                                      

  Age years (SD)                                                 853   62.9(12.8)     59.2(12.6)                                 68.7(9.8)[\*\*](#t001fn002){ref-type="table-fn"}    67.4(11.4)[\*\*](#t001fn002){ref-type="table-fn"}   60.2(12.0)                                            58.7(14.7)                                          63.6(12.8)                                           \<0.001[\*](#t001fn001){ref-type="table-fn"}

  Age range years                                                      27--92         28--89                                     48--90                                              27--90                                              40--92                                                27--87                                              32--92                                               

  Male sex                                                       846   575 (68.0%)    211 (67.2%)                                35 (66.0%)                                          172 (71.1%)                                         54 (79.4%)                                            19 (48.7%)[\*\*](#t001fn002){ref-type="table-fn"}   84 (64.6%)                                           0.027[\*](#t001fn001){ref-type="table-fn"}

  Indigenous                                                     521   71 (13.6%)     30 (13.4%)                                 2 (5.9%)                                            21 (12.7%)                                          8 (14.0%)                                             5 (18.5%)                                           5(35.7%)                                             0.145

  **Social Determinants**                                                                                                                                                                                                                                                                                                                                                                               

  Socioeconomic Status                                           846   846            314                                        51                                                  240                                                 68                                                    41                                                  132                                                  

  Most disadvantaged                                                   199 (23.5%)    88 (28.0%)                                 8 (15.7%)                                           58 (24.2%)                                          10 (14.7%)                                            8 (19.5%)                                           27 (20.5%)                                           

  Second most disadvantaged                                            188 (22.2%)    63 (20.1%)                                 14 (27.5%)                                          51 (21.3%)                                          14 (20.6%)                                            11 (26.8%)                                          35 (26.5%)                                           

  Middle                                                               130 (15.4%)    41 (13.1%)                                 8 (15.7%)                                           40 (16.7%)                                          15 (22.1%)                                            4 (9.8%)                                            22 (16.7%)                                           

  Second least disadvantaged                                           241 (28.5%)    83 (26.4%)                                 21 (41.2%)                                          71 (29.6%)                                          17 (25.0%)                                            16 (39.0%)                                          33 (25.0)                                            

  Least disadvantaged                                                  88 (10.4%)     39 (12.4%)                                 0                                                   20 (8.3%)                                           12 (17.6%)                                            2 (4.9%)                                            15 (11.4%)                                           0.497

  Geographic Remoteness                                          846   846            314                                        51                                                  240                                                 68                                                    41                                                  132                                                  

  Major city                                                           373 (44.1%)    144 (45.9%)                                18 (35.3%)                                          93 (38.8%)                                          33 (48.5%)                                            17 (41.5%)                                          68 (51.5%)                                           

  Inner regional area                                                  165 (19.5%)    57 (18.2%)                                 13 (25.5%)                                          50 (20.8%)                                          14 (20.6%)                                            9 (22.0%)                                           22 (16.7%)                                           

  Outer regional area                                                  194 (22.9%)    71 (22.6%)                                 14 (27.5%)                                          60 (25.0%)                                          13 (19.1%)                                            12 (29.3%)                                          24 (18.2%)                                           

  Remote area                                                          66 (7.8%)      16 (5.1%)                                  4 (7.8%)                                            25 (10.4%)                                          5 (7.4%)                                              3 (7.3%)                                            13 (9.8%)                                            

  Very remote area                                                     48 (5.7%)      26 (8.3%)                                  2 (3.9%)                                            12 (5.0%)                                           3 (4.4%)                                              0                                                   5 (3.8%)                                             0.261

  **Diabetes History**                                                                                                                                                                                                                                                                                                                                                                                  

  Type 2 diabetes                                                853   775 (90.9%)    283 (89.6%)                                51 (96.2%)                                          224 (92.6%)                                         62 (91.2%)                                            37 (90.2%)                                          118 (88.7%)                                          0.537

  Duration years (SD)                                            365   19.7(11.0)     19.1(9.4)                                  19.1(12.4)                                          21.9(12.5)                                          17.0(10.6)                                            14.6(11.7)                                          20.6(7.3)                                            0.056

  HbA1c % (SD)                                                   220   8.4(2.0)       8.7(2.1)                                   7.3(1.4)                                            8.3(2.0)                                            8.4(1.7)                                              8.8(3.1)                                            7.8(1.8)                                             0.270

  HbA1c mmol/mol [^a^](#t001fn003){ref-type="table-fn"}          220   68             72                                         56                                                  67                                                  68                                                    73                                                  62                                                   0.270

  BGL \>15mmol/L                                                 762   130 (17.1%)    62 (22.1%)                                 8 (16.0%)                                           33 (14.7%)                                          9 (15.0%)                                             9 (25.0%)                                           9 (8.1%)[\*\*](#t001fn002){ref-type="table-fn"}      0.015[\*](#t001fn001){ref-type="table-fn"}

  **Medical History**                                                                                                                                                                                                                                                                                                                                                                                   

  Hypertension                                                   853   211 (24.7%)    88 (27.8%)                                 29 (54.7%)[\*\*](#t001fn002){ref-type="table-fn"}   53 (21.9%)                                          18 (26.5%)                                            17 (41.5%)                                          6 (4.5%)[\*\*](#t001fn002){ref-type="table-fn"}      \<0.001[\*](#t001fn001){ref-type="table-fn"}

  Dyslipidaemia                                                  853   139 (16.3%)    54 (17.1%)                                 10 (18.9%)                                          51 (21.1%)                                          12 (17.6%)                                            7 (17.1%)                                           5 (3.8%)[\*\*](#t001fn002){ref-type="table-fn"}      0.001[\*](#t001fn001){ref-type="table-fn"}

  CVD                                                            853   90 (10.6%)     24 (7.6%)                                  18 (34.0%)[\*\*](#t001fn002){ref-type="table-fn"}   37 (15.3%)                                          6 (8.8%)                                              4 (9.8%)                                            1 (0.8%)[\*\*](#t001fn002){ref-type="table-fn"}      \<0.001[\*](#t001fn001){ref-type="table-fn"}

  CKD [^b^](#t001fn004){ref-type="table-fn"}                     853   60 (7.0%)      22 (7.0%)                                  5 (9.4%)                                            29 (12.0%)[\*\*](#t001fn002){ref-type="table-fn"}   1 (1.5%)                                              0                                                   3 (2.3%)                                             0.001[\*](#t001fn001){ref-type="table-fn"}

  Smoker                                                         853   37 (4.3%)      19 (6.0%)                                  3 (5.7%)                                            7 (2.9%)                                            5 (7.4%)                                              3 (7.3%)                                            0[\*\*](#t001fn002){ref-type="table-fn"}             0.035[\*](#t001fn001){ref-type="table-fn"}

  **Past Foot Treatment**                                                                                                                                                                                                                                                                                                                                                                               

  Podiatrist                                                     853   800 (93.8%)    293 (92.7%)                                51 (96.2%)                                          227 (93.8%)                                         60 (88.2%)                                            40 (100%)                                           128 (96.2%)                                          0.115

  GP                                                             853   20 (2.3%)      10 (3.2%)                                  1 (1.9%)                                            5 (2.1%)                                            2 (2.9%)                                              1 (2.4%)                                            1 (0.8%)                                             0.755

  Surgeon                                                        853   14 (1.6%)      8 (2.5%)                                   0                                                   3 (1.2%)                                            2 (2.9%)                                              0                                                   1 (0.8%)                                             0.450

  Physician                                                      853   21 (2.5%)      14 (4.4%)                                  0                                                   6 (2.5%)                                            0                                                     0                                                   1 (0.8%)                                             0.055

  Nurse                                                          853   53 (6.2%)      18 (5.7%)                                  4 (7.5%)                                            18 (7.4%)                                           7 (10.3%)                                             2 (4.9%)                                            4 (3.0%)                                             0.375

  Orthotist                                                      853   8 (0.9%)       1 (0.3%)                                   0                                                   7 (2.9%)[\*\*](#t001fn002){ref-type="table-fn"}     0                                                     0                                                   0                                                    0.015[\*](#t001fn001){ref-type="table-fn"}

  Other                                                          853   20 (2.3%)      10 (3.2%)                                  1 (1.9%)                                            9 (3.7%)                                            0                                                     0                                                   0                                                    0.118

  **Foot Disease History**                                                                                                                                                                                                                                                                                                                                                                              

  Previous foot ulcer                                            853   595 (69.8%)    202 (63.9%)                                30 (56.6%)[\*\*](#t001fn002){ref-type="table-fn"}   184 (76.0%)                                         46 (67.6%)                                            26 (63.4%)                                          107 (80.5%)[\*\*](#t001fn002){ref-type="table-fn"}   0.001[\*](#t001fn001){ref-type="table-fn"}

  Previous amputation                                            852   242 (28.4%)    74 (23.5%)                                 5 (9.4%)                                            83 (34.3%)[\*\*](#t001fn002){ref-type="table-fn"}   40 (58.8%)[\*\*](#t001fn002){ref-type="table-fn"}     7 (17.1%)                                           33 (24.8%)                                           \<0.001[\*](#t001fn001){ref-type="table-fn"}

  **Foot Risk Factors**                                                                                                                                                                                                                                                                                                                                                                                 

  Peripheral Neuropathy                                          726   617 (85.0%)    316 (100%)                                 0[\*\*](#t001fn002){ref-type="table-fn"}            242 (100.0%)                                        53 (80.3%)                                            0[\*\*](#t001fn002){ref-type="table-fn"}            6 (75.0%)                                            \<0.001[\*](#t001fn001){ref-type="table-fn"}

  PAD                                                            720   330 (45.8%)    0[\*\*](#t001fn002){ref-type="table-fn"}   53 (100.0%)                                         242 (100.0%)                                        32 (49.2%)[\*\*](#t001fn002){ref-type="table-fn"}     0[\*\*](#t001fn002){ref-type="table-fn"}            3 (100.0%)                                           \<0.001[\*](#t001fn001){ref-type="table-fn"}

  Foot deformity                                                 728   460 (63.2%)    209 (66.1%)                                24 (45.3%)                                          159 (66.0%)                                         47 (72.3%)                                            13 (32.5%)[\*\*](#t001fn002){ref-type="table-fn"}   8 (61.5%)                                            \<0.001[\*](#t001fn001){ref-type="table-fn"}

  Acute Charcot Foot                                             723   18 (2.5%)      13 (4.1%)                                  0                                                   4 (1.7%)                                            0                                                     1 (2.5%)                                            0                                                    0.191

  **Foot Ulcer Characteristics**                                                                                                                                                                                                                                                                                                                                                                        

  Ulcer area mm^2^ (SD) [^c^](#t001fn005){ref-type="table-fn"}   740   235.7(610.4)   184.7(449.2)                               210.5(351.6)                                        226.3(594.8)                                        585.8(941.3)[\*\*](#t001fn002){ref-type="table-fn"}   394.3(1317.7)                                       163.0(488.2)                                         \<0.001[\*](#t001fn001){ref-type="table-fn"}

  Deep ulcer [^d^](#t001fn006){ref-type="table-fn"}              843   66 (7.8%)      20 (6.5%)                                  2 (3.8%)                                            18 (7.5%)                                           9 (13.2%)                                             5 (12.8%)                                           12 (8.9%)                                            0.333

  Ulcer healing time                                             853                                                                                                                                                                                                                                                                                                                                    

  Healed \<3 months                                                    454 (53.2%)    177 (56.0%)                                29 (54.7%)                                          115 (47.5%)                                         43 (63.2%)                                            19 (46.3%)                                          71 (53.4%)                                           

  Healed 3--12 months                                                  222 (26.0%)    75 (23.7%)                                 10 (18.9%)                                          71 (29.3%)                                          15 (22.1%)                                            10 (24.4%)                                          41 (30.8%)                                           

  Not healed at 12 months                                              177 (20.8%)    64 (20.3%)                                 14 (26.4%)                                          56 (23.1%)                                          10 (14.7%)                                            12 (29.3%)                                          21 (15.8%)                                           0.188

  **Treatment**                                                                                                                                                                                                                                                                                                                                                                                         

  Debrided Ulcer                                                 849   765 (90.1%)    295 (93.4%)                                45 (86.5%)                                          206 (86.2%)                                         61 (89.7%)                                            35 (85.4%)                                          123 (92.5%)                                          0.063

  Dressing Appropriate                                           845   820 (97.0%)    303 (96.5%)                                51 (98.1%)                                          230 (96.2%)                                         66 (98.5%)                                            39 (97.5%)                                          131 (98.5%)                                          0.766

  Antibiotics Prescribed                                         851   58 (6.8%)      19 (6.0%)                                  1 (1.9%)                                            23 (9.6%)                                           6 (8.8%)                                              4 (9.8%)                                            5 (3.8%)                                             0.146

  Offloading Optimum                                             851   395 (46.4%)    138 (43.9%)                                24 (45.3%)                                          123 (50.8%)                                         25 (36.8%)                                            12(29.3%)[\*\*](#t001fn002){ref-type="table-fn"}    73 (54.9%)                                           0.016[\*](#t001fn001){ref-type="table-fn"}

  Footwear Appropriate                                           848   505 (59.6%)    206 (65.2%)                                31 (58.5%)                                          131 (54.8%)                                         36 (53.7%)                                            17 (42.5%)[\*\*](#t001fn002){ref-type="table-fn"}   84 (63.2%)                                           0.024[\*](#t001fn001){ref-type="table-fn"}

  Patient Educated                                               851   843(99.1%)     314 (99.7%)                                53 (100%)                                           238 (98.8%)                                         67 (98.5%)                                            39 (95.1%)                                          132 (99.2%)                                          0.104

  **Foot Infection Incidence**                                                                                                                                                                                                                                                                                                                                                                          

  All foot ulcer patients                                        853   342 (40.1%)    133 (42.1%)                                14 (26.4%)                                          106 (43.8%)                                         22 (32.4%)                                            13 (31.7%)                                          54 (40.6%)                                           0.111

  Ulcer healing time                                             853                                                                                                                                                                                                                                                                                                                                    

  Healed \<3 months                                              454   147 (32.4%)    67 (37.9%)                                 8 (27.6%)                                           40 (34.8%)                                          10 (23.3%)                                            3 (15.8%)                                           19 (26.8%)                                           0.152

  Healed 3--12 months                                            222   124 (55.9%)    40 (53.3%)                                 4 (40.0%)                                           41 (57.7%)                                          8 (53.3%)                                             5 (50.0%)                                           26 (63.4%)                                           0.785

  Not healed at 12 months                                        177   71 (40.1%)     26 (40.6%)                                 2 (14.3%)                                           25 (44.6%)                                          4 (40.0%)                                             5 (41.7%)                                           9 (42.9%)                                            0.487
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* *p* \< 0.05 for ANOVA (continuous) or Pearson's chi-squared (categorical)

\*\* Group(s) identified to be different to other groups using *p* \< 0.05 for adjusted Post hoc tests (continuous) or *p* \< 0.005 Fishers exact test with Bonferroni corrections (categorical)

^a^ HbA1c mmol/mol IFFC converted from HbA1c % NGSP

^b^ CKD is a combination of CKD and ESKD (End Stage Kidney Disease)

^c^ Ulcer area was measured by multiplying the longest edge x the widest edge in mm

^d^ Deep ulcer is an ulcer scoring a 2 or 3 on the University of Texas Diabetic Wound Classification System

BGL\>15 mmol/L: Blood Glucose Levels exceeding 15 mmol/L; CKD: Chronic Kidney Disease; CVD: Cardiovascular Disease; GP: General Practitioner; mm^2^: millimetres squared; PAD: Peripheral Arterial Disease; SD: Standard deviation.

[Table 1](#pone.0177916.t001){ref-type="table"} also shows 342 patients developed a foot infection during follow up for an overall incidence of 40.1%; including 32.4% incidence in DFUs healed \<3 month, 55.9% in DFUs healed between 3--12 month and 40.1% in DFUs that had not healed at 12 months (p\<0.05). However, there were no differences in foot infection incidence between different DFU types (*p*\>0.05).

[Table 2](#pone.0177916.t002){ref-type="table"} displays the univariate analyses that were conducted on the 720 patients with known DFU types. We excluded the 133 patients with unknown DFU types from the univariate analyses as they recorded large amounts of missing foot-related data, but in the other demographic, social determinant, diabetes history, past foot treatment and treatment variables with limited missing data they reported very few differences compared to known DFU types (*p*\>0.05) ([Table 1](#pone.0177916.t001){ref-type="table"}). The variables that achieved a crude univariate association and were included in the multivariate logistic regression model were age, sex, previous foot ulcer, peripheral neuropathy, foot deformity, deep ulcer and ulcer healing time (*p*\<0.1).

10.1371/journal.pone.0177916.t002

###### Univariate analysis for patients developing an infection of a diabetic foot ulcer (number (%) unless otherwise stated).

![](pone.0177916.t002){#pone.0177916.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 n     All\           No\            Infection      *p* Value
                                                                                      Infection                     
  -------------------------------------------------------------- ----- -------------- -------------- -------------- ----------------------------------------------
  **Patients**                                                   720   720            432(60.0%)     288(40.0%)     

  **Demographics**                                                                                                  

  Age years (SD)                                                 720   62.7(12.7)     63.9(12.5)     61.0(12.9)     0.003[\*](#t002fn001){ref-type="table-fn"}

  Male sex                                                       716   491 (68.6%)    305 (71.3%)    186 (64.6%)    0.071[\*](#t002fn001){ref-type="table-fn"}

  Indigenous                                                     507   66 (13.0%)     38 (13.1%)     28 (12.9%)     1.000

  **Social Determinants**                                                                                           

  Socioeconomic Status                                           714                                                

  Most disadvantaged                                                   172 (24.1%)    105 (24.5%)    67(23.5%)      

  Second most disadvantaged                                            153 (21.4%)    96 (22.4%)     57(20.0%)      

  Middle                                                               108 (15.1%)    69 (16.1%)     39(13.7%)      

  Second least disadvantaged                                           208 (29.1%)    112 (26.1%)    96(33.7%)      

  Least disadvantaged                                                  73 (10.2%)     47 (11.0%)     26(9.1%)       0.276

  Geographic Remoteness                                          714                                                

  Major city                                                           305 (42.7%)    174 (40.6%)    131(46.0%)     

  Inner regional area                                                  143 (20.0%)    86 (20.0%)     57(20.0%)      

  Outer regional area                                                  170 (23.8%)    104 (24.2%)    66(23.2%)      

  Remote area                                                          53 (7.4%)      37 (8.6%)      16(5.2%)       

  Very remote area                                                     43 (6.0%)      28 (6.5%)      15(5.3%)       0.434

  **Diabetes History**                                                                                              

  Type 2 diabetes                                                720   657 (91.3%)    397 (91.9%)    260 (90.3%)    0.536

  Duration years (SD)                                            360   19.7 (11.1)    19.6 (11.3)    19.8(10.8)     0.864

  HbA1c % (SD)                                                   205   8.5(2.1)       8.5(2.2)       8.4(1.8)       0.571

  HbA1c mmol/mol [^a^](#t002fn002){ref-type="table-fn"}          205   69             69             68             0.571

  BGL \>15mmol/L                                                 651   121 (18.6)     74 (18.9%)     47 (18.1%)     0.895

  **Medical History**                                                                                               

  Hypertension                                                   720   205 (28.5%)    131 (30.3%)    74 (25.7%)     0.206

  Dyslipidaemia                                                  720   134 (18.6%)    83 (19.2%)     51 (17.7%)     0.681

  CVD                                                            720   89 (12.4%)     55 (12.7%)     34 (11.8%)     0.799

  CKD [^b^](#t002fn003){ref-type="table-fn"}                     720   57 (7.9%)      34 (7.9%)      23 (8.0%)      1.000

  Smoker                                                         720   37 (5.1%)      21 (4.9%)      16 (5.6%)      0.809

  **Past Foot Treatment**                                                                                           

  Yes                                                            720                                                

  Podiatrist                                                     720   672 (93.3%)    402 (93.1%)    270 (93.8%)    0.831

  GP                                                             720   19 (2.6%)      12 (2.8%)      7 (2.4%)       0.962

  Surgeon                                                        720   13 (1.8%)      10 (2.3%)      3 (1.0%)       0.331

  Physician                                                      720   20 (2.8%)      14 (3.2%)      6 (2.1%)       0.487

  Nurse                                                          720   49 (6.8%)      26 (6.0%)      23 (8.0%)      0.381

  Orthotist                                                      720   8 (1.1%)       5 (1.2%)       3 (1.0%)       1.000

  Other                                                          720   20 (2.8%)      12 (2.8%)      8 (2.8%)       1.000

  **Foot Disease History**                                                                                          

  Previous foot ulcer                                            720   488 (67.8%)    270 (62.5%)    218 (75.7%)    \<0.001[\*](#t002fn001){ref-type="table-fn"}

  Previous amputation                                            719   209 (29.1%)    115 (26.7%)    94 (32.6%)     0.101

  **Foot Risk Factors**                                                                                             

  Peripheral Neuropathy                                          718   611 (85.1%)    353 (82.1%)    258 (89.6%)    0.008[\*](#t002fn001){ref-type="table-fn"}

  PAD                                                            717   327 (45.6%)    194 (45.2%)    133 (46.2%)    0.860

  Foot deformity                                                 715   452 (63.2%)    254 (59.2%)    198 (69.2%)    0.008[\*](#t002fn001){ref-type="table-fn"}

  Acute Charcot Foot                                             712   18 (2.5%)      7 (1.6%)       11 (3.9%)      0.108

  **Foot Ulcer Characteristics**                                                                                    

  Ulcer area mm^2^ (SD) [^c^](#t002fn004){ref-type="table-fn"}   624   249.2(629.9)   234.8(670.0)   270.1(567.2)   0.493

  Deep ulcer [^d^](#t002fn005){ref-type="table-fn"}              711   55 (7.7%)      22 (5.2%)      33(11.6%)      0.003[\*](#t002fn001){ref-type="table-fn"}

  Ulcer healing time                                             720                                                

      Healed \<3 months                                                383 (53.2%)    255 (59.0%)    128 (44.4%)    

      Healed 3--12 months                                              181 (25.1%)    83 (19.2%)     98 (34.0%)     

      Not healed at 12 months                                          156 (21.7%)    94 (21.8%)     62 (21.5%)     \<0.001[\*](#t002fn001){ref-type="table-fn"}

  **Treatment**                                                                                                     

  Debrided Ulcer                                                 716   642 (89.7%)    379 (88.1%)    263 (92.0%)    0.129

  Dressing Appropriate                                           712   689 (96.8%)    410 (95.8%)    279 (98.2%)    0.112

  Antibiotics Prescribed                                         718   53 (7.4%)      31 (7.2%)      22 (7.7%)      0.927

  Offloading Optimum                                             718   322 (44.8%)    189 (44.0%)    133 (46.2%)    0.609

  Footwear Appropriate                                           715   421 (58.9%)    258 (60.1%)    163 (57.0%)    0.447

  Patient Educated                                               718   711 (99.0%)    427 (99.1%)    284 (99.0%)    1.000
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

\* *p* \< 0.1

^a^ HbA1c mmol/mol IFFC converted from HbA1c % NGSP

^b^ CKD is a combination of CKD and ESKD (End Stage Kidney Disease)

^c^ Ulcer area was measured by multiplying the longest edge x the widest edge in mm

^d^ Deep ulcer is an ulcer scoring a 2 or 3 on the University of Texas Diabetic Wound Classification System

BGL\>15 mmol/L: Blood Glucose Levels exceeding 15 mmol/L; CKD: Chronic Kidney Disease; CVD: Cardiovascular Disease; GP: General Practitioner; mm^2^: millimetres squared; PAD: Peripheral Arterial Disease; SD: Standard deviation.

[Table 3](#pone.0177916.t003){ref-type="table"} displays the independent risk factors (Odds Ratio (95% confidence interval)) that predicted infection from the multivariate model and included: ulcers healed between 3--12 months (2.3 (1.6--3.3)), deep ulcers (2.2 (1.2--3.9)), peripheral neuropathy (1.8 (1.1--2.9)), previous foot ulcers (1.7 (1.2--2.4)), foot deformity (1.4 (1.0--2.0)), female gender (1.5 (1.1--2.1)) and years of age (0.98 (0.97--0.99)) (all *p*\<0.05). The above multivariate model explained approximately 12.0% of the variance of the infection outcome (Nagelkerke pseudo R^2^ = 0.120; *p*\<0.001).

10.1371/journal.pone.0177916.t003

###### Independent risk factors for developing an infection of a diabetic foot ulcer.

![](pone.0177916.t003){#pone.0177916.t003g}

  -------------------------------------------------------------------------------------------------------------------
  Risk Factor                   Odds Ratio (95% CI)                    *p* Value
  ----------------------------- -------------------------------------- ----------------------------------------------
  Age (years)                   0.98 (0.97--0.99)                      0.002[\*](#t003fn001){ref-type="table-fn"}

  Female                        1.52 (1.08--2.14)                      0.016[\*](#t003fn001){ref-type="table-fn"}

  Peripheral Neuropathy         1.77 (1.09--2.86)                      0.022[\*](#t003fn001){ref-type="table-fn"}

  Foot Deformity                1.44 (1.02--2.04)                      0.039[\*](#t003fn001){ref-type="table-fn"}

  Previous Foot Ulcer           1.66 (1.16--2.36)                      0.005[\*](#t003fn001){ref-type="table-fn"}

  Deep Ulcer                    2.16 (1.19--3.93)                      0.011[\*](#t003fn001){ref-type="table-fn"}

  Ulcer healing time                                                   \<0.001[\*](#t003fn001){ref-type="table-fn"}

      Healed \<3 months         Referent                               

      Healed 3--12 months       2.26 (1.55--3.29)                      \<0.001[\*](#t003fn001){ref-type="table-fn"}

      Not healed at 12 months   1.20 (0.80--1.81)                      0.373

  *Model Results*:              *Pseudo R*^*2*^: *0*.*120;*\           *Missing*: *17 (2*.*4%);*\
                                *Omnibus*: *df = 8*, *p = \<0*.*001*   *H&L*: *p = 0*.*088*
  -------------------------------------------------------------------------------------------------------------------

\* p \< 0.05

df: degrees of freedom; H&L: Hosmer and Lemeshow Goodness of Fit Test; Missing: Excluded missing cases; Omnibus: Omnibus Tests of Model Coefficients; Pseudo R2: Nagelkerke R2.

Discussion {#sec012}
==========

We found a 40% incidence of developing an infection prior to healing in a large sample of patients presenting with uninfected DFUs across a large representative region of Australia. The incidence increased from 32% in ulcers healed within 3 months to 56% in ulcers healed between 3--12 months. However, there was no statistical differences in the incidence of developing an infection between different types of DFUs. We identified several independent risk factors that predicted infection in patients presenting with an uninfected DFU, including presenting with a deep ulcer, a previous DFU history, peripheral neuropathy, foot deformity, at a younger age and female gender. Furthermore, DFUs that had not healed by 3 months after presentation were also a significant risk factor for infection. This study confirms, that regardless of the type of DFU presenting, a considerable proportion of people with DFUs will develop an infection prior to healing and common risk factors predict these infections.

To our knowledge only a paper by *Lavery and colleagues (2006)* has previously investigated the incidence of diabetic foot infection \[[@pone.0177916.ref005]\]. *Lavery* reported a 9% incidence of foot infection over a two-year follow up period in 1,666 patients with diabetes who were at different risks of developing DFU (low or high risk) \[[@pone.0177916.ref005]\]. They also indicated a 61% incidence of infection in a subgroup of 247 patients who developed a DFU (presenting with or without infection) \[[@pone.0177916.ref005]\]. Our study found a 40% incidence of infection over a one-year follow up period in 853 patients who first presented with an uninfected DFU. Additionally we found the incidence increased from 32% for ulcers healed \<3 months to 56% for ulcers healed between 3--12 months; however, the incidence for ulcers not healed at 12 months was no higher than those healed \<12 months. Furthermore whilst not ideal, comparing our 32--56% incidence findings to the 26--60% infection prevalence range reported by numerous DFU studies, seems to add further plausibility to our findings \[[@pone.0177916.ref003]--[@pone.0177916.ref005], [@pone.0177916.ref007]--[@pone.0177916.ref010]\]. Overall, interpreting these incidence findings together suggests the chance of developing an infection is double in those with "non-healing ulcers" (\>3 months healing time) compared to "healing ulcers" (\<3 months) \[[@pone.0177916.ref005], [@pone.0177916.ref010]\].

To our knowledge we are the first to investigate the incidence of developing infection in patients with different types of DFU and interestingly we found no differences. A recent previous study examining the prevalence of infection in different types of DFU also reported no differences \[[@pone.0177916.ref028]\]. This previous study reported very similar patient characteristics for those patients with different types of DFU to our study which also increases the potential generalisability of our findings \[[@pone.0177916.ref028]\]. Additionally, our overall DFU patient characteristics were very similar to those reported in other large international DFU studies, which further increases the generalisability of our findings \[[@pone.0177916.ref003], [@pone.0177916.ref008]--[@pone.0177916.ref010]\]. Lastly, our reported socio-demographic characteristics were very similar to the socio-demographic characteristics reported for the general Australian population \[[@pone.0177916.ref014], [@pone.0177916.ref019], [@pone.0177916.ref020]\]. Overall, these generalizable findings indicate that all clinicians treating patients with any type of DFU need to be incredibly vigilant to prevent infection and the subsequent significant risk of hospitalisation and amputation \[[@pone.0177916.ref005]\].

The risk factors we identified for developing foot infection in a large homogenous uninfected DFU population were similar to those identified in other studies investigating more heterogeneous DFU populations \[[@pone.0177916.ref005], [@pone.0177916.ref011]\], with perhaps some novel exceptions. Our identified risk factors with greatest odds of developing infection were highly consistent with these previous studies, including ulcers healed \>3months, deep ulcers, peripheral neuropathy, foot deformity and previous ulcer history \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]. It is not surprising that those DFUs that were deepest and had not healed for a longer duration were the leading risk factors for developing soft tissue infection as they expose a greater volume of soft tissue to infective organisms for a longer period of time \[[@pone.0177916.ref005], [@pone.0177916.ref029]\]. Additionally, it is not surprising that DFU patients with peripheral neuropathy and its resultant lack of protective sensation and immunopathy that contribute to delayed local inflammatory responses to infective organisms \[[@pone.0177916.ref030]\] is also a leading risk factor for developing diabetic foot infection \[[@pone.0177916.ref011]\]. Whilst foot deformity has not been specifically identified in previous studies, high plantar pressures have been \[[@pone.0177916.ref011]\] and foot deformity is often used as a surrogate marker of high plantar pressures \[[@pone.0177916.ref022]\]. Again high plantar pressures, especially in combination with neuropathy and deep ulcers, could be reasonably expected to expose a great volume of soft tissue that has limited inflammatory response to infective organisms \[[@pone.0177916.ref011]\]. Lastly, ours and previous studies did not capture participant's history of previous diabetic foot infection \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]; however, considering the high prevalence of infections in DFUs \[[@pone.0177916.ref003]--[@pone.0177916.ref005], [@pone.0177916.ref007]--[@pone.0177916.ref010]\], it is most probable that the identified risk factor of a previous DFU is also surrogate marker of a previous diabetic foot infection history \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]. Thus, it is not surprising that a history of any pathology is a risk factor for future pathology, in this case diabetic foot infection.

The novel risk factors identified in our study were that of younger age and female gender. To our knowledge, age or gender has not been previously identified as a risk factor for soft tissue diabetic foot infection \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]. In contrast to younger age, many studies have reported older age to be a risk factor for developing poor DFU outcomes \[[@pone.0177916.ref028], [@pone.0177916.ref031], [@pone.0177916.ref032]\]. However, one large previous study reported an association with younger age in patients with diabetes developing osteomyelitis \[[@pone.0177916.ref033]\]. Additionally, the mean ages reported from previous studies investigating large populations of DFU patients (approximately 65 years \[[@pone.0177916.ref008], [@pone.0177916.ref029], [@pone.0177916.ref031]\]) have generally been older when compared to studies investigating large populations of infected DFU patients (approximately 55 years \[[@pone.0177916.ref011], [@pone.0177916.ref033], [@pone.0177916.ref034]\]). It could be hypothesised that younger patients with equivalent DFUs are more physically active for longer durations then their older counterparts which may increase their exposure to infective organisms for longer durations. Also in contrast to female gender, it has been male gender that has been consistently reported to be a risk factor for the development of poor DFU outcomes \[[@pone.0177916.ref011], [@pone.0177916.ref029], [@pone.0177916.ref031], [@pone.0177916.ref032]\]. However, females have been reported to be at higher risk of other infections in patients with diabetes (such as different urinary tract infections) \[[@pone.0177916.ref035], [@pone.0177916.ref036]\] and perhaps female patients with diabetes are more susceptible to infection in general than males. Interestingly, recently published findings from a large retrospective analysis of outpatients with diabetes in the United States also reports patients with infected DFU were more likely to be younger and female compared to those with uninfected DFU \[[@pone.0177916.ref037]\]. Overall, these findings suggest the demographic risk factors for developing a DFU may be different to those for developing an infection of a DFU, and thus, more research investigating why these risk factors may be different is recommended

Interestingly, no other characteristics were identified as risk factors for infection in this study. This is somewhat surprising considering other studies have identified PAD in particular to be a risk factor for diabetic foot infection \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]. However, we hypothesise that, due to the heterogeneous populations investigated by these previous studies, PAD was more likely a risk factor for DFU \[[@pone.0177916.ref002]--[@pone.0177916.ref004]\] rather than diabetic foot infection in someone who has already developed a DFU. We suggest that once PAD has contributed to the development of a DFU, it is then the depth of tissue involvement, the duration of exposure, coupled with the immunopathy and lack of protective sensation from peripheral neuropathy that are the real culprits for developing a foot infection in the first instance \[[@pone.0177916.ref011], [@pone.0177916.ref030]\]. However, we suggest that once a DFU has become infected then underlying PAD may accelerate the progression of the infection and increase the risk of subsequent hospitalisation and amputation \[[@pone.0177916.ref003], [@pone.0177916.ref004]\].

Other large international population-based studies have identified socio-economic status, geographical remoteness and ethnicity to be associated with poor DFU outcomes \[[@pone.0177916.ref038], [@pone.0177916.ref039]\]. Two recent Australian studies also identified specific associations between indigenous Australians and DFU \[[@pone.0177916.ref040], [@pone.0177916.ref041]\]. However, our study which included patients from the diverse socio-demographic, geographical and indigenous backgrounds found in Australia \[[@pone.0177916.ref014], [@pone.0177916.ref032]\] could not find any associations with developing infection. Our findings were consistent with *Peters et al* that could not find any association between socio-demographic factors and diabetic foot infection in the United States \[[@pone.0177916.ref011]\]. Additionally, they were consistent with a large study by *Holman et al (2015)* investigating DFU healing outcomes across the United Kingdom who also could not find any association with socio-demographic factors \[[@pone.0177916.ref010]\]. *Holman* hypothesised that the universal best practice standard of DFU care provided to patients attending the services in their study may have counteracted any typical socio-demographic factor influence on negative DFU outcomes \[[@pone.0177916.ref010]\] and our findings seem to support their hypothesis.

Although, our risk factor findings were relatively consistent with previous studies \[[@pone.0177916.ref005], [@pone.0177916.ref011]\], our study is the first to report the variance predicted from our model containing these risk factors. Collectively our multivariate model explained approximately 12% of the predicted variance for developing infection according to our reported pseudo R^2^. This predicted variance indicates that there must be other risk factors for developing infection in patients with DFU that were not investigated in our study. Thus, we firstly recommended that any future studies investigate the risk factors identified in our study in addition to a range of other diabetes severity, physical activity, plantar pressures, microbial isolates, inflammatory makers and treatment factors in both best practice and standard care settings \[[@pone.0177916.ref042]\]. Secondly, it is recommended that future studies investigate for any differences in risk factor profiles for developing mild, moderate and severe diabetic foot infection outcomes. Lastly, it is recommended that clinicians managing patients with a DFU should be particularly vigilant in their provision of best practice care if those patients present with a DFU that is deep, have a previous ulcer history, peripheral neuropathy, foot deformity, are of younger age or female. This vigilance should be heightened again if the ulcer has not healed by 3 months. Any improved strategies to prevent infection in patients with DFU should also begin to reduce the significant burden of hospitalisation and amputation in these patients.

Limitations and strengths {#sec013}
-------------------------

This study had a number of limitations. First, it was secondary analysis of a prospective state-wide clinical diabetic foot database that primarily collects DFU healing and recurrence outcomes for clinical benchmarking and research purposes and not primarily for infection outcomes. However it could be argued that this database's primary focus on DFU also provides some strength to our study. Second, much missing data was reported in relation to the specific diabetes severity variables (diabetes duration, HbA1c) and for this reason we did not include them in our multivariate models. Therefore, our study was unable to properly investigate if these variables were risk factors for infected DFU. Third, we defined PAD using a toe pressure of \<70mmHg, which is arguably a lower threshold than the \<0.8 ankle brachial index used by aforementioned studies investigating risk factors for infection \[[@pone.0177916.ref005], [@pone.0177916.ref011]\], and this may have meant we over-reported PAD. Fourth, we excluded patients that did not have infection status recorded at baseline or during follow up; however, the proportion of patients fitting these criteria was small. Fifth, we followed up patients whose DFU had not healed for only 12-months and this may have contributed to an underestimation of our infection incidence for those not healed at 12-months. Sixth, we were only able to obtain dichotomous data reporting if an infection occurred prior to healing and not the date of infection. Thus, like other papers in this field \[[@pone.0177916.ref005], [@pone.0177916.ref011]\] we were able to report incidence rates and perform logistic regression; however, we were unable to report time-to-event survival analyses which may have provided additional more detailed findings. Seventh, although the QHRFF best practice protocol used in this study aligns with national diabetic foot guideline recommendations \[[@pone.0177916.ref022]\] and recommends at least fortnightly care for DFU patients \[[@pone.0177916.ref012]\], we can only assume this best practice follow up care was provided. Additionally, we may have missed some infections and other treatments (such as some revascularisation procedures) that were potentially managed elsewhere between visits. Last, no information about microbial isolates or inflammatory markers was collected to determine their association with infection development \[[@pone.0177916.ref042]\].

This study also had a number of strengths. First, this study's sample size was the largest of any study longitudinally investigating DFU patients for infection \[[@pone.0177916.ref005], [@pone.0177916.ref011]\], was comparable in sample size to other large longitudinal studies investigating other DFU outcomes \[[@pone.0177916.ref005], [@pone.0177916.ref008]--[@pone.0177916.ref010]\] and had a very high retention rate. Second, the characteristics of included DFU patients and DFU types in our study were generalizable to other regions as we reported very similar characteristics to those reported in other large DFU studies \[[@pone.0177916.ref003], [@pone.0177916.ref008]--[@pone.0177916.ref010]\]. Third, the included patients in our study were representative of the diverse socio-demographic backgrounds reported in the general Australian population \[[@pone.0177916.ref014], [@pone.0177916.ref019], [@pone.0177916.ref020]\]. Fourth, all variables were captured on a data collection instrument and database that has been reported to be valid and reliable to collect DFU-related variables, including infection \[[@pone.0177916.ref012], [@pone.0177916.ref013], [@pone.0177916.ref015]\]. Fifth, DFU patients were treated according to a best practice protocol on their first visit \[[@pone.0177916.ref012], [@pone.0177916.ref022]\]. Furthermore, this protocol recommends at least fortnightly clinical care and data collection using the QHRFF for DFU patients \[[@pone.0177916.ref022]\], and thus, it is assumed patients also received frequent best practice care and data collection during follow up \[[@pone.0177916.ref012]\]. Last, we identified independent risk factors for diabetic foot infection that were adjusted for age, sex and ulcer healing time using a widely recommended multivariate logistic regression analysis model \[[@pone.0177916.ref026], [@pone.0177916.ref027]\], which makes the findings of our study comparable to other similar studies of diabetic foot infection \[[@pone.0177916.ref005], [@pone.0177916.ref011]\]. However, an additional strength of our study's analysis was that we were the first to report the approximate variance that our identified risk factors collectively predicted for diabetic foot infection.

Conclusions {#sec014}
===========

This study of a large representative Australian population of patients presenting to Diabetic Foot Services with uninfected diabetic foot ulcers, confirms that a considerable proportion will develop an infection prior to healing, regardless of their ulcer type. Risk factors for developing an infection included initially presenting with a deep ulcer, having had a previous ulcer, having peripheral neuropathy, having a foot deformity, being of younger age and female. In addition an ulcer that had not healed \<3 months of this presentation doubled the odds of developing infection. It is recommended that future investigations in this population focus on demographic, diabetes severity, physical activity, microbial isolates and inflammatory marker explanatory variables and different diabetic foot infection severity outcomes. The results of this study should assist to improve risk profiling and treatment of diabetic foot ulcers to prevent future infections.
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